Blueprint Medicines Corporation (NASDAQ:BPMC) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k
-
0

Blueprint Medicines Corporation (NASDAQ:BPMC) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07.Submission of Matters to a Vote of Security Holders.

Blueprint Medicines Corporation (the “Company”) held its annual meeting of stockholders on June 20, 2018.The following is a summary of the matters voted on at the meeting.

1.

The Company’s stockholders elected Daniel S. Lynch, George D. Demetri, M.D. and Lynn Seely, M.D. as Class III directors, each to serve until the 2021 annual meeting of stockholders and until his or her successor has been duly elected and qualified.The results of the stockholders’ vote with respect to the election of such Class III directors were as follows:

Votes For

Votes Withheld

Broker Non-Votes

Daniel S. Lynch

 32,852,065 6,048,688 2,467,641

George D. Demetri, M.D.

 32,196,702 6,704,051 2,467,641

Lynn Seely, M.D.

 33,062,895 5,837,858 2,467,641

2.

The Company’s stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers. The results of the stockholders’ non-binding, advisory vote with respect to compensation paid to the Company’s named executive officers were as follows:

Votes For

Votes Against

Votes Abstaining

Broker Non-Votes
38,403,708 492,764 4,281 2,467,641

3.

The Company’s stockholders determined that future advisory votes on the compensation paid to its named executive officers would be held every year. The results of the stockholders’ non-binding, advisory vote with respect to the frequency of future advisory votes on the compensation paid to the Company’s named executive officers were as follows:

1 Year

2 Years

3 Years

Votes Abstaining

BrokerNon-Votes
38,805,413 2,111 91,145 2,084 2,467,641

After taking into consideration the foregoing voting results and the prior recommendation of the Company’s Board of Directors (the “Board”) in favor of an annual stockholder advisory vote on the compensation of the Company’s named executive officers, the Board intends to hold future advisory votes on the compensation of the Company’s named executive officers every year.

4.

The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting for the fiscal year ending December 31, 2018. The results of the stockholders’ vote with respect to such ratification were as follows:

Votes For

Votes Against

Votes Abstaining
41,340,067 7,941 20,386


About Blueprint Medicines Corporation (NASDAQ:BPMC)

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options. The Company has developed a small molecule drug pipeline in cancer and a genetic disease. The Company’s drug candidate, BLU-285, targets KIT Exon 17 mutants and PDGFRa D842V, which are abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. It is engaged in developing BLU-285 for patients with systemic mastocytosis (SM), a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor (GIST). Its drug candidate, BLU-554, targets FGFR4, a kinase that is aberrantly activated and is a driver of disease in a defined subset of patients with hepatocellular carcinoma (HCC).